Pay in 4 interest-free payments of $5.19 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
The primary risk is therapeutic failurepatients may experience rising blood glucose levels, inadequate appetite suppression, or weight regain if using compromised medication
Adults with Overweight & Comorbidities: Individuals with a BMI of 27 kg/m or higher who also have at least one weight-related medical condition, such as hypertension (high blood pressure), type 2 diabetes, or dyslipidemia (high cholesterol)
Tirzepatide injections are typically administered once a week
Surgeons generally look for weight fluctuations of less than 5 pounds over a 3-month period as evidence of true stability
Products sold online for research use are not approved for human use
Clinical data from the SURMOUNT-1 trial showed that gastrointestinal adverse events were dose-dependent: 39% at 5 mg, 46% at 10 mg, and 49% at 15 mg
US$ 22.73
US$ 28.86
US$ 27.46
US$ 25.89
